Recent Medical press releases & news

Presswire is the leading news platform where businesses, educational institutions, news reporters, etc. come together to share compelling news stories that transform opinions and impact lives. Presswire has an extensive media contact list for press releases, reaching millions of contacts. We ensure that your story lands on the right business desks and the right mass media outlets. To begin your press release distribution, send your stories to Presswire or by filling out the form here.

1

Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC

 

[PRESSWIRE] Vienna - 23rd February 2022 -- Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).

1

ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — February 3, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Drs. Guy Rouleau and Alain Dagher to its scientific advisory board (SAB).

ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE - Mass. — January 27, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Dr. Cheryl Wellington to its scientific advisory board (SAB).

1

Using Smart Sensors and Cloud-based Analytics, Canary’s 20-minute Handheld COVID-19 Saliva-based Molecular Test with PCR Quality Results Achieves CE Mark

• Rapid molecular PCR-like accurate saliva-based test delivers 95% sensitivity and 98% specificity in symptomatic and asymptomatic individuals with SARS-CoV-2 including variants
• Designed for point-of-care (POC) diagnosis, ease of use, rapid and cost-effective mass-screening
• A mobile-enabled, multiplex platform and connected solution enables efficient real-time reporting of results, track & trace, and surveillance

ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — January 18, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has initiated a program to develop monoclonal antibodies to treat schizophrenia and other chronic mental illnesses. Schizophrenia is a clinical term for a severely disabling neuropsychiatric disease that disrupts employment, families and communities, and likely has heterogenous biological origins.

ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — January 7, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Biotech Showcase 2022 virtual panel discussion to be held on Jan. 11, 2022 from 8 AM to 9 AM PST.

1

Theramex Names Camilla Harder Hartvig As New Chief Commercial Officer

 

[PRESSWIRE] London - 13 December 2021 -- Theramex is excited to announce the appointment of Camilla Harder Hartvig as Chief Commercial Officer as of 1st January 2022 particularly during a pivotal moment in the company’s development in Consumer Healthcare.

1

CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant

 

[PRESSWIRE] Austria - 10.12.21 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).

1

Study shows, inhaling active form of hydrogen "suisonia" effective for Post COVID-19 syndrome

 

[PRESSWIRE] Japan - 21 October, 2021 -- Post COVID-19 syndrome, a developing world-wide problem may be alleviated by Japan originated medical device "suisonia".

1

Mr. Line Dempsey of Riccobene Associates Family Dentistry, President-Elect of CLEAR

 

[PRESSWIRE] US - 29 September, 2021 -- Riccobene Associates Family Dentistry is pleased to announce the election of Mr. Line Dempsey as President-Elect for the Council on Licensure, Enforcement, and Regulation (CLEAR).